Soaring merger & acquisition activity in life sciences threatens competition and reduces customer options, both to patients and to pharma and biotech firms seeking help with growing pharmacovigilance and regulatory filing requirements. Alan White of Arriello explains why it has never been more important to choose wisely.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2019/11/Choice-Matters_-Diminishing-Options-as-a-Result-of.pdf” width=”100%” height=”900px” style=”border:0;”]